Pharmacokinetics, safety, and tolerability of a new patritumab formulation in patients with advanced, refractory solid tumors.

被引：4
作者：
Papadopoulos, Kyriakos P.
Moore, Kathleen N.
Lush, Richard
Desai, Madhuri
Mahmood, Syed
Beckman, Robert A.
Mendell-Harary, Jeanne
机构：
[1] START South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[2] Peggy & Charles Stephenson Oklahoma Canc Ctr, Oklahoma City, OK USA
[3] H Lee Moffitt Canc Ctr & Res Inst Inc, Tampa, FL USA
[4] Daiichi Sankyo, Edison, NJ USA
[5] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14026
引用
收藏
页数：1
相关论文
共 50 条
[31]   Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours [J].
Kan Yonemori ;
Kenji Tamura ;
Makoto Kodaira ;
Koshi Fujikawa ;
Tamotsu Sagawa ;
Taito Esaki ;
Tsuyoshi Shirakawa ;
Fumihiko Hirai ;
Yuki Yokoi ;
Toshio Kawata ;
Ben Hatano ;
Yasuo Takahashi .
Cancer Chemotherapy and Pharmacology, 2016, 78 :525-531
[32]   Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors. [J].
Puzanov, I. ;
Sarantopoulos, J. ;
Gilbert, J. ;
Mahalingam, D. ;
Chap, L. I. ;
Deng, H. ;
Zhu, M. ;
McCaffery, I. ;
Friberg, G. R. ;
Rosen, L. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[33]   A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors. [J].
Johnson, Melissa Lynne ;
Wang, Judy Sing-Zan ;
Falchook, Gerald Steven ;
Charlton, Julie ;
MacDonald, Alexander ;
Strickland, Donald ;
Jones, Suzanne Fields ;
Pease, Elizabeth J. ;
Brugger, Wolfram ;
Burris, Howard A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34]   A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors. [J].
Piha-Paul, Sarina Anne ;
Sharma, Sunil ;
Shih, Chengkon ;
O'Neil, Bert H. ;
Zhou, Qinghong ;
Ding, Yuli ;
Ou, Na ;
Yu, Tingting .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35]   Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. [J].
Barnes, Tristan Alexandra ;
Amir, Eitan ;
Templeton, Arnoud J. ;
Garcia, Susana Gomez ;
Navarro, Beatriz ;
Seruga, Bostjan ;
Ocana, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36]   A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors [J].
Ma, Yuxiang ;
Fang, Wenfeng ;
Zhao, Hongyun ;
Bathena, Sai Praneeth ;
Tendolkar, Amol ;
Sheng, Jennifer ;
Zhang, Li .
ONCOLOGIST, 2021, 26 (04) :E549-E566
[37]   Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment [J].
Grechko, Nikolay ;
Skarbova, Viera ;
Tomaszewska-Kiecana, Monika ;
Ramlau, Rodryg ;
Centkowski, Piotr ;
Drew, Yvette ;
Dziadziuszko, Rafal ;
Zemanova, Milada ;
Beltman, Jeri ;
Nash, Eileen ;
Habeck, Jenn ;
Liao, Mingxiang ;
Xiao, Jim .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (02) :259-270
[38]   Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment [J].
Nikolay Grechko ;
Viera Skarbova ;
Monika Tomaszewska-Kiecana ;
Rodryg Ramlau ;
Piotr Centkowski ;
Yvette Drew ;
Rafal Dziadziuszko ;
Milada Zemanova ;
Jeri Beltman ;
Eileen Nash ;
Jenn Habeck ;
Mingxiang Liao ;
Jim Xiao .
Cancer Chemotherapy and Pharmacology, 2021, 88 :259-270
[39]   PHASE I STUDY OF THE PHARMACOKINETICS AND TOLERABILITY OF EVEROLIMUS IN CHINESE PATIENTS WITH ADVANCED SOLID TUMORS [J].
Xu, B. ;
Shen, L. ;
Ye, D. ;
Jappe, A. ;
Cherfi, A. ;
Wang, H. ;
Yuan, R. ;
Wu, Y. .
ANNALS OF ONCOLOGY, 2010, 21 :178-178
[40]   A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors [J].
Mody, Kabir ;
Mansfield, Aaron S. ;
Vemireddy, Lalitha ;
Nygren, Peter ;
Gulbo, Joachim ;
Borad, Mitesh .
INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) :684-692
12345